Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2004-02-25 Capital/Financing Update
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Nanogen License - Additional Value Realized 1 page
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the Australian Stock Exchange announcing a financial update related to the realization of additional value from a license agreement with Nanogen. It details the conversion and sale of warrants into shares and the resulting profit contribution for the current financial year. The document is short (1387 characters) and serves as an announcement of a financial event rather than a full financial report or detailed earnings release. It does not contain comprehensive financial statements or detailed analysis, nor is it a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and realization of value from securities transactions.
2004-02-25 English
Grants License to LabCorp of USA 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 9 February 2004, reporting that Genetic Technologies Limited (GTG) has granted a license to LabCorp for its non-coding patents. It discusses the licensing agreement, confidentiality of financial details, and the withdrawal of a legal action by LabCorp against GTG. The document also mentions ongoing legal action involving GTG and another company. The content is an announcement of a licensing agreement and related legal updates, not a financial report, earnings release, or detailed management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Legal Proceedings Report because it primarily announces a licensing deal and related legal developments. It is not a regulatory filing or report publication announcement since it contains substantive information about the license and legal status. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories but involves material company information disclosed to the market.
2004-02-08 English
Progress Report re: Gtech Int. Resources Ltd 1 page
Regulatory Filings Classification · 95% confidence The document is a brief update letter addressed to the Australian Stock Exchange Limited regarding Gtech International Resources Limited, a subsidiary of Genetic Technologies Limited. It provides historical ownership details, recent financial status, and strategic direction. The document is short (1414 characters) and does not contain detailed financial statements, comprehensive analysis, or regulatory certifications. It is an announcement-type update about subsidiary status and ownership, not a full financial report or regulatory filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2004-02-01 English
Commitments Test Entity - Second Quarter Report 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report' and contains detailed financial data including consolidated cash flow statements for the quarter ended 31 December 2003. It includes operating, investing, and financing cash flows, payments to directors, reconciliation of cash, and compliance statements. The document is a comprehensive quarterly financial report with substantive financial data and analysis, not merely an announcement or certification. The presence of detailed financial tables and notes confirms it is an Interim / Quarterly Report.
2004-01-29 English
Response to ASX Query re:Share Price 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a letter exchange between Genetic Technologies Limited and the Australian Stock Exchange (ASX) regarding a price enquiry about recent movements in the company's securities price and trading volume. The ASX requests information about any undisclosed material information that could explain the price change, compliance with listing rules, and potential trading halts. The company's response confirms no undisclosed information and compliance with listing rules. This document is a regulatory communication related to stock price movements and compliance, not a financial report, earnings release, or management discussion. It is a regulatory filing responding to a stock exchange inquiry, fitting the category of Regulatory Filings (RNS). The document length is about 5,654 characters, which is short and focused on compliance and disclosure rather than financial data or report publication. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2004-01-21 English
Change of Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the changes in securities holdings of a director, including number of shares held before and after the change, nature of the interest, and transaction details. There is no financial performance data, earnings information, or report publication. The content clearly matches the definition of a Director's Dealing report, which involves personal share transactions by company directors and executives (insider trades). The document length is 6222 characters, sufficient to contain detailed transaction information. Therefore, the correct classification is DIRS (Director's Dealing).
2004-01-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.